Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study

Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

Background: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD). Objective: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy,in relieving behavioral and psychological symptoms of dementia (BPSD). Methods: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial. Results: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress. Conclusion: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.

Original languageEnglish
Pages (from-to)15-19
Number of pages5
JournalJournal of Alzheimer's Disease
Volume51
Issue number1
DOIs
StatePublished - 27 Feb 2016

Bibliographical note

Publisher Copyright:
© 2016 - IOS Press and the authors. All rights reserved.

Keywords

  • Alzheimer's disease
  • behavioral and psychological symptoms of dementia
  • cannabis
  • tetrahydrocannabinol

Fingerprint

Dive into the research topics of 'Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study'. Together they form a unique fingerprint.

Cite this